Borrow it
- African Studies Library
- Alumni Medical Library
- Astronomy Library
- Fineman and Pappas Law Libraries
- Frederick S. Pardee Management Library
- Howard Gotlieb Archival Research Center
- Mugar Memorial Library
- Music Library
- Pikering Educational Resources Library
- School of Theology Library
- Science & Engineering Library
- Stone Science Library
The Resource Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber
Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber
Resource Information
The item Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Boston University Libraries.This item is available to borrow from all library branches.
Resource Information
The item Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber represents a specific, individual, material embodiment of a distinct intellectual or artistic creation found in Boston University Libraries.
This item is available to borrow from all library branches.
- Summary
- Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety and effectiveness, and suggests how public policy changes could mitigate liability-based sources of inefficient decisions of pharmaceutical companies
- Language
- eng
- Extent
- 1 online resource (xx, 96 pages)
- Contents
-
- Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency
- Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims
- Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability
- Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown
- CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury
- Isbn
- 9780833079916
- Label
- Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals
- Title
- Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals
- Statement of responsibility
- Steven Garber
- Language
- eng
- Summary
- Liability effects on the economic performance of the pharmaceutical industry play a prominent role in the debate about the economic effects of product liability in the United States. The author analyzes incentive effects on company decisions, implications for economic outcomes such as drug safety and effectiveness, and suggests how public policy changes could mitigate liability-based sources of inefficient decisions of pharmaceutical companies
- Cataloging source
- MERUC
- http://library.link/vocab/creatorName
- Garber, Steven
- Illustrations
- illustrations
- Index
- no index present
- LC call number
- KF1297.D7
- LC item number
- G37 2013eb
- Literary form
- non fiction
- Nature of contents
-
- dictionaries
- bibliography
- http://library.link/vocab/relatedWorkOrContributorName
- JSTOR Open Access
- http://library.link/vocab/subjectName
-
- Products liability
- Pharmaceutical industry
- MEDICAL
- BUSINESS & ECONOMICS
- Pharmaceutical industry
- Products liability
- United States
- Label
- Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber
- Bibliography note
- Includes bibliographical references
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Color
- multicolored
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
-
- Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency
- Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims
- Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability
- Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown
- CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury
- Dimensions
- unknown
- Extent
- 1 online resource (xx, 96 pages)
- Form of item
- online
- Isbn
- 9780833079916
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Other physical details
- illustrations
- Specific material designation
- remote
- Stock number
- 22573/ctt297h2m
- System control number
-
- (OCoLC)849912765
- (OCoLC)ocn849912765
- Label
- Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber
- Bibliography note
- Includes bibliographical references
- Carrier category
- online resource
- Carrier category code
-
- cr
- Carrier MARC source
- rdacarrier
- Color
- multicolored
- Content category
- text
- Content type code
-
- txt
- Content type MARC source
- rdacontent
- Contents
-
- Cover; Title Page; Copyright; Preface; Contents; Figure and Tables; Summary; Acknowledgments; Abbreviations; CHAPTER ONE: Introduction; CHAPTER TWO: Conceptual Framework for the Analyses; Positive Analysis: Effects of Liability Exposure on Company Decisions and Economic Outcomes; Company Decisions and Economic Outcomes; Conceptualizing Company Decisionmaking; What Determines Whether Companies Respond to Liability Exposure?; What Kinds of Conclusions Are Possible from the Positive Analytic Approach?; Normative Analysis: Economic Efficiency of Effects of Liability Exposure; Economic Efficiency
- Identifying Sources of InefficiencyCHAPTER THREE: The Legal and Institutional Settings; Food and Drug Administration Regulation; Preapproval Regulations; Post-Market Regulations; Product-Liability Law for Prescription Drugs; Manufacturing Defects; Design Defects; Warnings Defects; Regulatory Compliance Defenses (RCDs); Other Legal Issues and Practices; Personal-Injury Causation; Class Actions Alleging Personal Injuries; Class Actions Alleging Financial Injuries; Judicial Gatekeeping of Expert Evidence; U.S. Supreme Court Decisions on Sizes of Punitive Damages; Medical Monitoring Claims
- Congregation and Coordination of Related LawsuitsSettlements of Mass Torts; CHAPTER FOUR: Pharmaceutical Mass Torts During the 1990s and 2000s; Mass Torts Resulting in Especially Large Payouts by Defendants; Fen-Phen Diet Pills; Baycol; Rezulin; Vioxx; Hormone Replacement Therapies-Premarin, Provera, and Prempro; Zyprexa; Mass Tort Attempts Resulting in Substantially Smaller Payouts by Defendants; Norplant; Childhood Vaccines and Autism; Other Mass Tort Attempts That Have Largely Failed for Plaintiffs; Summing Up; Mass Drug-Related Injuries; Mass Torts; Financial Incentives to Avoid Liability
- Roles of Punitive DamagesControversies About Injury Causation; Transaction Costs of Unsuccessful Mass Tort Attempts; CHAPTER FIVE: Preemption of Pharmaceutical Failure-to-Warn Claims; Federal Preemption Law; Purported Economic Effects of Failure-to-Warn Claims; Economic Arguments Supporting Preemption; Economic Arguments Opposing Preemption; Preemption of Failure-to-Warn Claims for Generic Drugs; Would Failure-to-Warn Litigation Pass a Social Cost-Benefit Test?; Sources of Confusion in the Preemption Debate; The Overall Economic Efficiency of FTW Litigation Is Unknown
- CHAPTER SIX: Incentives Stemming from Other Litigation Affecting Safety and EffectivenessActions Brought by the U.S. Department of Justice; State Consumer Protection Acts-Background and Controversies; Safety- and Effectiveness-Related Litigation Brought by State Attorneys General; Safety- and Effectiveness-Related Financial-Injury Litigation Brought by Private Parties; Shareholder Suits Pertaining to Pharmaceutical Safety and Effectiveness; Summing Up; CHAPTER SEVEN: In Conclusion; Major Legal Developments Since 1990; Product Liability for Personal Injury
- Dimensions
- unknown
- Extent
- 1 online resource (xx, 96 pages)
- Form of item
- online
- Isbn
- 9780833079916
- Media category
- computer
- Media MARC source
- rdamedia
- Media type code
-
- c
- Other physical details
- illustrations
- Specific material designation
- remote
- Stock number
- 22573/ctt297h2m
- System control number
-
- (OCoLC)849912765
- (OCoLC)ocn849912765
Library Locations
-
African Studies LibraryBorrow it771 Commonwealth Avenue, 6th Floor, Boston, MA, 02215, US42.350723 -71.108227
-
-
Astronomy LibraryBorrow it725 Commonwealth Avenue, 6th Floor, Boston, MA, 02445, US42.350259 -71.105717
-
Fineman and Pappas Law LibrariesBorrow it765 Commonwealth Avenue, Boston, MA, 02215, US42.350979 -71.107023
-
Frederick S. Pardee Management LibraryBorrow it595 Commonwealth Avenue, Boston, MA, 02215, US42.349626 -71.099547
-
Howard Gotlieb Archival Research CenterBorrow it771 Commonwealth Avenue, 5th Floor, Boston, MA, 02215, US42.350723 -71.108227
-
-
Music LibraryBorrow it771 Commonwealth Avenue, 2nd Floor, Boston, MA, 02215, US42.350723 -71.108227
-
Pikering Educational Resources LibraryBorrow it2 Silber Way, Boston, MA, 02215, US42.349804 -71.101425
-
School of Theology LibraryBorrow it745 Commonwealth Avenue, 2nd Floor, Boston, MA, 02215, US42.350494 -71.107235
-
Science & Engineering LibraryBorrow it38 Cummington Mall, Boston, MA, 02215, US42.348472 -71.102257
-
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.bu.edu/portal/Economic-effects-of-product-liability-and-other/94lKcw9nlTA/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.bu.edu/portal/Economic-effects-of-product-liability-and-other/94lKcw9nlTA/">Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.bu.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.bu.edu/">Boston University Libraries</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Item Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.bu.edu/portal/Economic-effects-of-product-liability-and-other/94lKcw9nlTA/" typeof="Book http://bibfra.me/vocab/lite/Item"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.bu.edu/portal/Economic-effects-of-product-liability-and-other/94lKcw9nlTA/">Economic effects of product liability and other litigation involving the safety and effectiveness of pharmaceuticals, Steven Garber</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.bu.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.bu.edu/">Boston University Libraries</a></span></span></span></span></div>